The purpose of this study is to investigate wether noninvasive ventilation by nose mask during the night has additional benefits next to pulmonary rehabiliatation in patients with severe hypercapnic COPD.

Condition	Intervention	Phase
Pulmonary Disease, Chronic Obstructive	Device: Noninvasive positive pressure ventilation	Phase III

Further Study Details: 

Primary Outcomes: Health related Quality of Life measured by the Chronic Respiratory Questionnaire
Secondary Outcomes: Activities of daily Living; Dyspnea (MRC, BDI, Borg); Exercise tolerance (Cycle ergometer test, 6-MWD, ISWT, ESWT); Pulmonary function testing; Sleepquality (polysomnografie); Respiratory muscle activity (EMG); Respiratory muscle strenght (PImax, PEmax)
Expected Total Enrollment:  100

Several randomised controlled trials in patients with stable Chronic Obstructive Pulmonary Disease (COPD) have demonstrated that pulmonary rehabilitation (PR) improves dyspnoea, exercise tolerance, and health-related quality of life. Research in this field has been important in our department for several years. The first study in this respect was started in 1986 comparing outpatient rehabilitation with rehabilitation in the community in patients with severe COPD. This study showed that rehabilitation supervised by a physical therapist in the community is effective for a long period in contrast to outpatient rehabilitation. In 1990 the second study started showing that positive initial benefits of home based rehabilitation on quality of life can be maintained for 18 months if the patients visit the local physical therapist once a month.

However, less positive effects of rehabilitation have been reported in the more severe patients. Because of dyspnoea due to inspiratory muscle fatigue patients may not receive an adequate training stimulus, and therefore rehabilitation might be less effective. In these more severe patients alternative therapies are needed. These non-pharmacological treatments include nutritional suppletion, oxygen therapy, lung transplantation, lung volume reduction surgery and ventilatory support.

The last few years a discussion within the 4 home mechanical ventilation centres (HMV) in the Netherlands has been started about the role of chronic ventilatory support in end-stage COPD. Theoretically, it might be effective because: 1) a resetting of the respiratory centre may reduce daytime PaCO2; 2) a better internal milieu (pH, PaO2, PaCO2) may improve peripheral muscle function; 3) resting the respiratory muscles during the night may increase their daytime strength and endurance; 4) a reduction in the number of nocturnal arousals may improve the quality of sleep. Nevertheless, none of these mechanisms has been proven and currently there is no evidence that NIPPV should be given to stable patients with COPD. While several randomised controlled trials (RCT’s) on NIPPV have been published with different outcomes, a recent meta-analysis did not show beneficial effects on blood gasses, lung function, respiratory muscle function and walking distance. In contrast several uncontrolled studies did show clear benefits from NIPPV on gas-exchange, dyspnoea and quality of life. Possible reasons for these conflicting outcomes are differences in: 1) selection of patients, 2) adequacy of ventilatory support, 3) length of ventilatory support. Interestingly, it seems that studies with a positive outcome included mainly patients with hypercapnia, suggesting this as an important selection criterion.

Our hypothesis is that long term NIPPV in hypercapnic patients with COPD may improve the effects of rehabilitation at home regarding health status, ADL function, dyspnoea and exercise tolerance. Secondly, we like to elucidate the exact mechanisms why NIPPV might be effective in this group of patients.

Comparison: patients who receive noninvasive ventialtion during the night while following a pulmonary rehabilitation program with patients who only follow a rehabilitation program without receiving the noninvasive ventilation.

Ages Eligible for Study:  40 Years   -   75 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• COPD (FEV1< 50%, Tiffeneau < 70%)
• Dyspnoea on exertion and a reduced exercise capacity
• Age 75 years or less
• PaCO2 > 6.0 kPa at rest without oxygen

Exclusion Criteria:

• Cardial / neuromuscular diseases limiting a successful rehabilitation
• Obstructive Sleep apnoea syndrome: AHI > 10
• Previous exposure to chronic NIPPV
• Participation in a pulmonary rehabilitation program less than 18 months ago

Please refer to this study by ClinicalTrials.gov identifier  NCT00135538

Marieke L Duiverman      0031-505338229    M.Duiverman@cvr.umcg.nl
Peter J Wijkstra, MD      0031-503613200    P.J.Wijkstra@int.umcg.nl

Netherlands
      University medical Hospital Groningen, Groningen,  9700 RB,  Netherlands; Recruiting

Study chairs or principal investigators

Marieke L Duiverman,  Principal Investigator,  University Medical Center Groningen   

Study ID Numbers:  RECOVER1
Last Updated:  August 25, 2005
Record first received:  August 25, 2005
ClinicalTrials.gov Identifier:  NCT00135538
Health Authority: Netherlands: Independent Ethics Committee
ClinicalTrials.gov processed this record on 2005-08-30